Axsome plots new fibromyalgia trial after FDA refuses to review former Pfizer candidate
Axsome Therapeutics has hit a costly snag in its mission to bring esreboxetine to market for fibromyalgia. The FDA has refused to review the CNS specialist’s new drug application for the asset, with the agency determining that one of the two trials in the filing was not up to snuff.
Axsome Therapeutics has hit a costly snag in its mission to bring esreboxetine to market for fibromyalgia. The FDA has refused to review the CNS specialist’s new drug application for the asset, with the agency determining that one of the two trials in the filing was not up to snuff.
